ConductScience.org, home

Paper39558776

Are we there yet? CAR-T therapy in multiple myeloma.

Mirvis E and 1 other. Br J Haematol, 2024. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Are we there yet? CAR-T therapy in multiple myeloma. Papers, record 39558776. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39558776

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Are we there yet? CAR-T therapy in multiple myeloma.
PubMed
Journal
Br J Haematol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.42, provisional
iCite
Revised in PubMed
2026-09-23
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mirvis EEitanhttps://orcid.org/0000-0002-3337-5111
2Benjamin RReubenhttps://orcid.org/0000-0003-1434-0594

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple MyelomaMajor topic
Immunotherapy, AdoptiveMajor topic
Receptors, Chimeric AntigenMajor topic
Humans
B-Cell Maturation Antigen
T-Lymphocytes

References98

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135287669Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells.J Transl Med2022https://conductscience.org/library/papers/35287669PubMed
235105265A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.Leuk Lymphoma2022https://conductscience.org/library/papers/35105265PubMed
337414060
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Lancet Oncol2023https://conductscience.org/library/papers/37414060PubMed
437339964Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma.Nat Commun2023https://conductscience.org/library/papers/37339964PubMed
537591876Long-term outcomes of allogeneic stem cell transplant in multiple myeloma.Blood Cancer J2023https://conductscience.org/library/papers/37591876PubMed
635125241Harnessing natural killer cells for the treatment of multiple myeloma.Semin Oncol2022https://conductscience.org/library/papers/35125241PubMed
734175021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet2021https://conductscience.org/library/papers/34175021PubMed
8259390634-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.Nat Med2015https://conductscience.org/library/papers/25939063PubMed
937844355Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.Biomed Pharmacother2023https://conductscience.org/library/papers/37844355PubMed
1037653344Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.Nat Med2023https://conductscience.org/library/papers/37653344PubMed
1136446823Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma.Nat Commun2022https://conductscience.org/library/papers/36446823PubMed
1229435173CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes.Oncotarget2018https://conductscience.org/library/papers/29435173PubMed
1335702871Bispecific T-cell engagers for treatment of multiple myeloma.Am J Hematol2023https://conductscience.org/library/papers/35702871PubMed
1436064867Potential solutions for manufacture of CAR T cells in cancer immunotherapy.Nat Commun2022https://conductscience.org/library/papers/36064867PubMed
1531900462'Off-the-shelf' allogeneic CAR T cells: development and challenges.Nat Rev Drug Discov2020https://conductscience.org/library/papers/31900462PubMed
1636881785Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.J Clin Oncol2023https://conductscience.org/library/papers/36881785PubMed
1733499253Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.Int J Mol Sci2021https://conductscience.org/library/papers/33499253PubMed
1834445701CAR T-Cell Therapy in Hematological Malignancies.Int J Mol Sci2021https://conductscience.org/library/papers/34445701PubMed
1930718503Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.Blood Cancer J2019https://conductscience.org/library/papers/30718503PubMed
2032034142CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide.Nat Commun2020https://conductscience.org/library/papers/32034142PubMed

See all 98 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42780650A 3D engineered multiple myeloma niche for evaluating CAR T cell therapy.Front Bioeng Biotechnol2026https://conductscience.org/library/papers/42780650PubMed
414286222025 Update of Cellular Immunotherapy for Plasma Cell Disorders.Turk J Haematol2026https://conductscience.org/library/papers/41428622PubMed
41410870Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies.Cancer Immunol Immunother2025https://conductscience.org/library/papers/41410870PubMed
39558776Are we there yet? CAR-T therapy in multiple myeloma.Br J Haematol2024https://conductscience.org/library/papers/39558776PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FCRL583416PubTator's text mininghttps://conductscience.org/library/genes/83416NCBI Gene
GPRC5D55507PubTator's text mininghttps://conductscience.org/library/genes/55507NCBI Gene
SLAMF757823PubTator's text mininghttps://conductscience.org/library/genes/57823NCBI Gene
TNFRSF17608PubTator's text mininghttps://conductscience.org/library/genes/608NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39558776

GET https://conductscience.org/api/papers/v1/39558776/references?page=2